Post-Trade Analysis: Arcus Biosciences Inc (RCUS) Climbs 5.11, Closing at 15.84

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $15.07 in the prior trading day, Arcus Biosciences Inc (NYSE: RCUS) closed at $15.84, up 5.11%. In other words, the price has increased by $5.11 from its previous closing price. On the day, 1.38 million shares were traded. RCUS stock price reached its highest trading level at $17.09 during the session, while it also had its lowest trading level at $15.55.


Our goal is to gain a better understanding of RCUS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.22 and its Current Ratio is at 5.22. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.

On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 27 ’24 when Jarrett Jennifer sold 11,551 shares for $17.55 per share. The transaction valued at 202,720 led to the insider holds 215,253 shares of the business.

Jarrett Jennifer sold 13,449 shares of RCUS for $240,941 on Mar 18 ’24. The Chief Operating Officer now owns 226,804 shares after completing the transaction at $17.92 per share. On Feb 27 ’24, another insider, Jarrett Jennifer, who serves as the Chief Operating Officer of the company, sold 34,070 shares for $20.11 each. As a result, the insider received 685,148 and left with 240,253 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1440695552 and an Enterprise Value of 584695680. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.08 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 2.467 whereas that against EBITDA is -2.426.

Stock Price History:

Over the past 52 weeks, RCUS has reached a high of $25.47, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is -3.08%, while the 200-Day Moving Average is calculated to be -7.45%.

Shares Statistics:

The stock has traded on average 641.77K shares per day over the past 3-months and 703140 shares per day over the last 10 days, according to various share statistics. A total of 75.50M shares are outstanding, with a floating share count of 48.04M. Insiders hold about 47.18% of the company’s shares, while institutions hold 54.28% stake in the company. Shares short for RCUS as of 1715731200 were 7544850 with a Short Ratio of 11.76, compared to 1713139200 on 6842934. Therefore, it implies a Short% of Shares Outstanding of 7544850 and a Short% of Float of 17.22.

Earnings Estimates

Investors are eagerly awaiting the insights provided by 9.0 analysts currently analyzing and rating the stock of Arcus Biosciences Inc (RCUS).On average, analysts expect EPS of -$1.13 for the current quarter, with a high estimate of -$0.8 and a low estimate of -$1.53, while EPS last year was -$1.04. The consensus estimate for the next quarter is -$1.0, with high estimates of -$0.51 and low estimates of -$1.47.

Analysts are recommending an EPS of between -$2.35 and -$4.92 for the fiscal current year, implying an average EPS of -$3.63. EPS for the following year is -$4.35, with 10.0 analysts recommending between -$2.41 and -$5.48.

Revenue Estimates

8 analysts predict $24.99M in revenue for the current quarter. It ranges from a high estimate of $40M to a low estimate of $10M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $30.3MFor the next quarter, 8 analysts are estimating revenue of $36.24M. There is a high estimate of $100M for the next quarter, whereas the lowest estimate is $22M.

A total of 9 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $265M, while the lowest revenue estimate was $100M, resulting in an average revenue estimate of $210.14M. In the same quarter a year ago, actual revenue was $117MBased on 10 analysts’ estimates, the company’s revenue will be $181.22M in the next fiscal year. The high estimate is $524.84M and the low estimate is $90M.

Most Popular